logo
Rosen Law Firm Urges Alto Neuroscience, Inc. (NYSE: ANRO) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Rosen Law Firm Urges Alto Neuroscience, Inc. (NYSE: ANRO) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Globe and Mail5 days ago
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto's initial public offering conducted on or about February 2, 2024 (the 'IPO'); and/or (ii) securities between February 2, 2024 and October 22, 2024. Alto describes itself as a 'clinical-stage biopharmaceutical company in the U.S.'
For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.
The Allegations: Rosen Law Firm is Investigating the Allegations that Alto Neuroscience, Inc. (NYSE: ANRO) Misled Investors Regarding its Business Operations.
According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements regarding Alto's business, operations, and prospects. Specifically, the offering documents and defendants made false and/or misleading statements and/or failed to disclose that: (1) ALTO-100 was less effective in treating major depressive disorder ('MDD') than defendants had led investors to believe; (2) accordingly, ALTO-100's clinical, regulatory, and commercial prospects were overstated; (3) as a result, Alto's business and/or financial prospects were overstated; and (4) as a result, Alto's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
What Now: You may be eligible to participate in the class action against Alto Neuroscience, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by September 19, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump's tariff threats against Canada face legal hurdles ahead of August deadline
Trump's tariff threats against Canada face legal hurdles ahead of August deadline

National Post

time11 minutes ago

  • National Post

Trump's tariff threats against Canada face legal hurdles ahead of August deadline

Donald Trump's plan to realign global trade faces its latest legal barrier this week in a federal appeals court — and Canada is bracing for the U.S. president to follow through on his threat to impose higher tariffs. Article content While Trump set an Aug. 1 deadline for countries to make trade deals with the United States, the president's ultimatum has so far resulted in only a handful of frameworks for trade agreements. Article content Article content Article content Deals have been announced for Japan, Vietnam, Indonesia, the Philippines and the United Kingdom — but Trump indicated last week that an agreement with Canada is far from complete. Article content Trump sent a letter to Prime Minister Mark Carney threatening to impose 35 per cent tariffs if Canada doesn't make a trade deal by the deadline. The White House has said those duties would not apply to goods compliant with the Canada-U.S.-Mexico Agreement on trade. Article content Article content Countries around the world will also be watching as Trump's use of a national security statute to hit nations with tariffs faces scrutiny in the United States Court of Appeals for the Federal Circuit. Article content The U.S. Court of International Trade ruled in May that Trump does not have the authority to wield tariffs on nearly every country through the use of the International Economic Emergency Powers Act of 1977. Article content The act, usually referred to by the acronym IEEPA, gives the U.S. president authority to control economic transactions after declaring an emergency. No previous president had ever used it for tariffs and the U.S. Constitution gives power over taxes and tariffs to Congress. Article content Article content The Trump administration quickly appealed the lower court's ruling on the so-called 'Liberation Day' and fentanyl-related tariffs and arguments are set to be heard in the appeal court on Thursday. Article content George Mason University law professor Ilya Somin called Trump's tariff actions a 'massive power grab.' Somin, along with the Liberty Justice Center, is representing the American small businesses.

U.S. says tariff deadline of Aug 1 is firm, no extensions
U.S. says tariff deadline of Aug 1 is firm, no extensions

CTV News

timean hour ago

  • CTV News

U.S. says tariff deadline of Aug 1 is firm, no extensions

U.S. President Donald Trump listens to members of the media after he arrived at Prestwick Airport in Ayrshire, Scotland, Friday, July 25, 2025.(AP Photo/Jacquelyn Martin) WASHINGTON — The U.S. deadline of August 1 for imposing tariffs on its trading partners is firm and there will be no extensions, U.S. Commerce Secretary Howard Lutnick said Sunday. 'So no extensions, no more grace periods. August 1, the tariffs are set. They'll go into place. Customs will start collecting the money, and off we go,' Lutnick told 'Fox News Sunday.' After the levies kick in, U.S. President Donald Trump -- who was negotiating Sunday in Scotland with European Union officials -- is still willing to keep talking, Lutnick said. Of the Europeans, Lutnick said, 'You know they're hoping they make a deal, and it's up to President Trump, who's the leader of this negotiating table. We set the table.' So far five countries have struck deals with the Trump administration ahead of the Friday deadline as it tries to overhaul the global system of largely free trade by slapping tariffs on countries that the United States deems as engaging in unfair practices. These five are Britain, Vietnam, Indonesia the Philippines, and Japan. The levies they accepted are often higher than the new base rate of 10 percent that the United States has applied to most countries since April. But they are far below the levels the Trump administration threatened to impose if no deal were reached. AFP

Codex Labs to Exhibit at The Society for Pediatric Dermatology's 50th Annual Meeting
Codex Labs to Exhibit at The Society for Pediatric Dermatology's 50th Annual Meeting

Globe and Mail

timean hour ago

  • Globe and Mail

Codex Labs to Exhibit at The Society for Pediatric Dermatology's 50th Annual Meeting

Seattle, Wash. - July 22nd, 2025 - Codex Labs, a biotech skincare company focused on microbiome-friendly solutions, is honored to participate in The Society for Pediatric Dermatology's (SPD) 50th Annual Meeting. Taking place from July 23rd to 26th at The Westin Seattle, the event will celebrate five decades of advancing pediatric dermatology through education, research, and collaboration. "Codex Labs is delighted to be attending The Society for Pediatric Dermatology's 50th Annual Meeting and presenting a novel plant-based biotech eczema lotion and cleanser for children as young as 3 weeks old,' says founder and CEO Dr. Barbara Paldus. 'We believe that these new topicals, when combined and targeted with pre- and probiotics, will usher in a future of highly effective, steroid-free alternatives for the management of pediatric atopic dermatitis." The SPD comprises over 1,800 members worldwide, including pediatricians, dermatologists, pediatric dermatologists, and other healthcare professionals. At this year's milestone 50th SPD Annual Meeting, Codex Labs will be one of many organizations gathering to support the advancement of pediatric dermatology. The SPD's 50th Annual Meeting will take place over four days and feature networking opportunities, support group discussions, lecture sessions, companies and exhibitors showcasing their products, and organizations dedicated to pediatric dermatology research and advancement. Some key topics highlighted at this year's meeting include infections, medications and therapies, psoriasis and inflammatory skin conditions, tumors and neoplasms, vascular lesions, and more. Codex Labs will be attending this year's 50th Annual Meeting and sponsoring the Early Career Networking Reception on Wednesday, July 23rd at 6:00 pm. This event is for medical doctors completing a fellowship or those out of training for five years or less, where they can share experiences and connect with other young dermatologists. Dr. Jessica Maloh, Naturopathic Doctor and Head of Naturopathic Medicine at Codex Labs, will be attending the event and presenting a research poster that highlights the use of oral probiotics as adjunctive interventions for acne. 'Acne is one of the most common skin conditions affecting adolescents, often impacting not only the skin, but also self-esteem and quality of life,' says Dr. Maloh. 'At the SPD, I'm excited to share a summary of the research on the adjunctive use of oral probiotics in acne management- an intervention that may complement conventional dermatologic treatments like antibiotics and oral isotretinoin. Integrative strategies like this have been found to enhance acne treatment efficacy while also supporting the gut microbiome.' Codex Labs is honored to participate in the 50th Annual Meeting and looks forward to showcasing its products and findings. Dr. Maloh invites guests to the Networking Reception and to visit her team's presentation to learn more about their skincare breakthroughs and the latest in integrative dermatology research. Event Details: Location: The Westin Seattle, located at 1900 5th Ave, Seattle, WA 98101. For more information about Codex Labs and its products, please visit If you are interested in learning more about Codex Labs' participation in The SPD's 50th Annual Meeting, please contact About Codex Labs: Based in Silicon Valley and led by scientist Dr. Barb Paldus, Codex Labs is committed to creating highly effective, clinically proven, microbiome-supporting skin-gut-brain-biome solutions that contain potent, biotech-derived plant-based actives. Codex Labs' products focus on restoring/protecting the skin barrier, managing inflammation, and addressing skin conditions associated with aging, acne, eczema, and psoriasis. The brand has been heralded by integrative dermatologists and naturopathic doctors for creating the next generation of effective, vegan, cruelty-free, and sustainable plant-based solutions.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store